All Stories

  1. Improving the Management of Patients with Heart Failure with Reduced Ejection Fraction in Clinical Practice: The Case for Angiotensin Receptor–Neprilysin Inhibitor
  2. How to Assess Pulmonary Circulation and Right Heart Chambers in Systemic Sclerosis Patients?
  3. Utility of Clustering in Mortality Risk Stratification in Pulmonary Hypertension
  4. MicroRNA and Heart Failure: A Novel Promising Diagnostic and Therapeutic Tool
  5. Pleiotropic Effects of Direct Oral Anticoagulants in Chronic Heart Failure and Atrial Fibrillation: Machine Learning Analysis
  6. Circulating Biomarkers in Pulmonary Arterial Hypertension: An Update
  7. Endothelial Function in Pulmonary Arterial Hypertension: From Bench to Bedside
  8. Beyond Natriuretic Peptides: Unveiling the Power of Emerging Biomarkers in Heart Failure
  9. Cardiovascular Biomarkers in Cardio-Oncology: Antineoplastic Drug Cardiotoxicity and Beyond
  10. Exploring the Prognostic Performance of MECKI Score in Heart Failure Patients with Non-Valvular Atrial Fibrillation Treated with Edoxaban
  11. Improvement in Left and Right Ventricular Function after Introduction of SGLT2 Inhibitors in Heart Failure Outpatients with Reduced Ejection Fraction
  12. The Role of Genetics in the Management of Heart Failure Patients
  13. The Long-Term Benefit of Sacubitril/Valsartan in Patients with HFrEF: A 5-Year Follow-Up Study in a Real World Population
  14. Fibrosis-specific biomarkers and interstitial fibrosis in hypertrophic cardiomyopathy
  15. Introduction of SGLT2 Inhibitors and Variations in Other Disease-Modifying Drugs in Heart Failure Patients: A Single-Centre Real-World Experience
  16. Relationship between the strain measures of left atrial function and heart failure worsening
  17. SGLT2 Inhibitors Introduction and Changes of the Other Disease Modifiers’ Drugs in Heart Failure Patients: A Single Center Real World Experience
  18. The Role of Congestion Biomarkers in Heart Failure with Reduced Ejection Fraction
  19. Sacubitril/Valsartan and Cognitive Outcomes in Heart Failure With Reduced Ejection
  20. Imaging Modality to Guide Left Atrial Appendage Closure: Current Status and Future Perspectives
  21. SGLT2 Inhibitors: Statins or ACE-Inhibitors of the 21st Century?
  22. Left Atrial Functional Remodeling in Patients with Chronic Heart Failure Treated with Sacubitril/Valsartan
  23. Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: Real-World Experience from Italy (the REAL.IT Study)
  24. Does the Measurement of Ejection Fraction Still Make Sense in the HFpEF Framework? What Recent Trials Suggest
  25. Gliflozins: From Antidiabetic Drugs to Cornerstone in Heart Failure Therapy—A Boost to Their Utilization and Multidisciplinary Approach in the Management of Heart Failure
  26. LEAP Virtual Visit Assessment (VIVA): a structured protocol for virtual visits for patients with heart failure
  27. Meet the Editorial Board Member
  28. Left atrial functional reverse remodeling assessed by speckle tracking echocardiography in a real-life population of patients with chronic heart failure after therapy with sacubitril/valsartan
  29. Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients
  30. Biomarkers in Cardiorenal Syndrome
  31. Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins?
  32. Effects of Sacubitril/Valsartan in Patients with High Arrhythmic Risk and an ICD: A Longitudinal Study
  33. Infection, atherothrombosis and thromboembolism beyond the COVID-19 disease: what similar in physiopathology and researches
  34. Chronic thromboembolic pulmonary hypertension mimicking coronary artery disease
  35. Echocardiographic score for prediction of pulmonary hypertension at catheterization: the Daunia Heart Failure Registry
  36. Novel AKAP9 mutation and long QT syndrome in a patient with torsades des pointes
  37. Sacubitril/valsartan eligibility and outcomes in the ESC‐EORP‐HFA Heart Failure Long‐Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM‐HF trial, ESC guidelines, and real world
  38. Acute heart failure congestion and perfusion status – impact of the clinical classification on in‐hospital and long‐term outcomes; insights from the ESC‐EORP‐HFA Heart Failure Long‐Term Registry
  39. Advanced heart failure: non-pharmacological approach
  40. Double de novo mutations in dilated cardiomyopathy with cardiac arrest
  41. Hospitalization cost reduction with sacubitril-valsartan implementation in a cohort of patients from the Daunia Heart Failure Registry
  42. Malignancies and outcome in Takotsubo syndrome: a meta-analysis study on cancer and stress cardiomyopathy
  43. Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years
  44. Dose-dependent efficacy of β-blocker in patients with chronic heart failure and atrial fibrillation
  45. Clinical and prognostic impact of chronotropic incompetence in patients with hypertrophic cardiomyopathy
  46. Prognostic significance of the echocardiographic estimate of pulmonary hypertension and of right ventricular dysfunction in acute decompensated heart failure. A pilot study in HFrEF patients
  47. Right heart dysfunction: from pathophysiologic insights to therapeutic options: a translational overview
  48. Exercise physiology in pulmonary hypertension patients with and without congenital heart disease
  49. Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?
  50. Retrospective Analysis of Endocrine Dysfunctions in a Population of Adult Polytransfused Patients: Correlation of GH-IGF1 Axis Alteration with Cardiac Performance
  51. Macitentan Use in a Neurofibromatosis Type 1 Patient With Pulmonary Hypertension and External Jugular Phlebectasia
  52. Fenofibrate and Dyslipidemia: Still a Place in Therapy?
  53. Exhaled Nitric Oxide and Exhaled Breath Temperature as Potential Biomarkers in Patients with Pulmonary Hypertension
  54. A new educational program in heart failure drug development: the Brescia international master program
  55. Don’t stop at first glance: pulmonary artery angiosarcoma mimicking chronic thromboembolic pulmonary hypertension
  56. Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry
  57. Direct oral anticoagulants versus standard triple therapy in atrial fibrillation and PCI: meta-analysis
  58. The role of cardiopulmonary exercise tests in pulmonary arterial hypertension
  59. “PAFIYAMA” syndrome; further evidence on a novel clinical entity
  60. Redefining biomarkers in heart failure
  61. Influence of various therapeutic strategies on right ventricular morphology, function and hemodynamics in pulmonary arterial hypertension
  62. Direct oral anti-coagulants compared to vitamin-K antagonists in cardioversion of atrial fibrillation: an updated meta-analysis
  63. Mineralocorticoid receptor antagonists for heart failure: a real-life observational study
  64. Liver disease and heart failure: Back and forth
  65. Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension
  66. Cardiopulmonary exercise test predicts right heart catheterization
  67. Nailfold capillaroscopic changes in patients with idiopathic pulmonary arterial hypertension and systemic sclerosis-related pulmonary arterial hypertension
  68. Angiotensin-converting enzyme inhibitors, angiotensin II receptors antagonists, beta-blockers and ivabradine as supportive therapy in pulmonary hypertension: Drug safety and tolerability
  69. Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a long-term comparison
  70. Pre-hospital electrocardiogram triage with telemedicine near halves time to treatment in STEMI: A meta-analysis and meta-regression analysis of non-randomized studies
  71. Scared for the scar: fearsome impact of acute cardiovascular disease on perceived kinesiophobia (fear of movement)
  72. Cardiac magnetic resonance imaging for the diagnosis and follow-up of Loeffler's endocarditis
  73. Combined therapy with beta-blockers and ACE-inhibitors/angiotensin receptor blockers and recurrence of Takotsubo (stress) cardiomyopathy: A meta-regression study
  74. Direct oral anti-coagulants compared with vitamin-K inhibitors and low-molecular-weight-heparin for the prevention of venous thromboembolism in patients with cancer: A meta-analysis study
  75. Respiratory drive in patients with chronic heart failure and central sleep apnea: Data from the Daunia Heart Failure Registry
  76. Prognostic role of β‐blocker selectivity and dosage regimens in heart failure patients. Insights from the MECKI score database
  77. Fenofibrate plus simvastatin in combined dyslipidemia: pros and cons
  78. Meet our Editorial Board Member
  79. Heart failure and anemia: Effects on prognostic variables
  80. Tako-Tsubo cardiomyopathy complicated by paroxysmal supraventricular tachycardia
  81. Association therapy with macitentan added to sildenafil in a thalassemic patient with pulmonary hypertension
  82. Incidence of atrial fibrillation is associated with age and gender in subjects practicing physical exercise: A meta-analysis and meta-regression analysis
  83. ABCB1 SNP rs4148738 modulation of apixaban interindividual variability
  84. Therapy of Stress (takotsubo) Cardiomyopathy: Present Shortcomings and Future Perspectives
  85. Big atria, little P waves: unexpected mismatch between chamber volume and electrocardiogram signal in “false” atrial fibrillation
  86. Management of heart failure in the new era
  87. Drug treatment rates with beta-blockers and ACE-inhibitors/angiotensin receptor blockers and recurrences in takotsubo cardiomyopathy: A meta-regression analysis
  88. Inferior ST-Elevation Acute Myocardial Infarction or an Inferior-Lead Brugada-like Electrocardiogram Pattern Associated With the Use of Pregabalin and Quetiapine?
  89. Meet Our Associate Editor:
  90. Exercise tolerance can explain the obesity paradox in patients with systolic heart failure: data from the MECKI Score Research Group
  91. Cardiopulmonary exercise test and sudden cardiac death risk in hypertrophic cardiomyopathy
  92. Heart Failure Progression in Hypertrophic Cardiomyopathy – Possible Insights From Cardiopulmonary Exercise Testing –
  93. Intermittent vertebral flow in asymptomatic progression of aortic dissection
  94. Tissue Doppler Imaging predicts central sleep apnea in patients with chronic heart failure: data from the Daunia Registry
  95. Additional Prognostic Value of EAS index in predicting the occurrence of rehospitalizations in chronic heart failure: data from the Daunia Heart Failure Registry
  96. Lower cardiovascular mortality with atorvastatin and rosuvastatin vs simvastatin: Data from “moderate-intensity” statin users in an observational registry on chronic heart failure (Daunia Heart Failure Registry)
  97. Prognostic role of atrial fibrillation in patients affected by chronic heart failure. Data from the MECKI score research group
  98. Typical Takotsubo syndrome and McConnell's phenomenon: What else lies beneath?
  99. HIV‐associated pulmonary arterial hypertension: from bedside to the future
  100. Chronic thromboembolic pulmonary hypertension
  101. Atrioventricular 2
  102. Pulmonary arterial hypertension in a chronic lymphocytic leukemia patient in treatment with rituximab
  103. Exercise Performance Is a Prognostic Indicator in Elderly Patients With Chronic Heart Failure – Application of Metabolic Exercise Cardiac Kidney Indexes Score –
  104. Renal Function and Peak Exercise Oxygen Consumption in Chronic Heart Failure With Reduced Left Ventricular Ejection Fraction
  105. Pleiotropic Effects of Statin in Therapy in Heart Failure: A Review
  106. Far-field ventricular sensing defects and syncope in a patient with right subclavian VDD pace-maker
  107. Early inflammatory cytokine response: A direct comparison between spontaneous coronary plaque destabilization vs angioplasty induced
  108. Deceptive meaning of oxygen uptake measured at the anaerobic threshold in patients with systolic heart failure and atrial fibrillation
  109. Tissue Doppler Imaging in Coronary Heart Diseases and Heart Failure: An Up to Date
  110. Functional Improvement in Pulmonary Arterial Hypertension Patients Treated With Ivabradine
  111. Troponin release after newborns ergot poisoning: Heart, lung or circulation?
  112. Role of Vasoactive Intestinal Peptide in Chronic Obstructive Pulmonary Disease with Pulmonary Hypertension
  113. Novelty in Treatment of Pulmonary Fibrosis: Pulmonary Hypertension Drugs and Others
  114. Blunted inflammatory response in STEMI patients timely reperfused
  115. Sildenafil improves clinical and functional status of an elderly postmenopausal female with ‘out of proportion’ PH associated with left heart disease
  116. Statin Therapy in Heart Failure: For Good, for Bad, or Indifferent?
  117. Peak Myocardial Acceleration during Isovolumic Relaxation Time Predicts the Occurrence of Rehospitalization in Chronic Heart Failure: Data from the Daunia Heart Failure Registry
  118. Tako-Tsubo cardiomyopathy recurrence in an elderly woman firstly diagnosed with acute myocardial infarction: How many cold cases to be reclassified?
  119. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry
  120. EURObservational Research Programme: regional differences and 1‐year follow‐up results of the Heart Failure Pilot Survey (ESC‐HF Pilot)
  121. Inflammatory activation is related to glucose impairment in diabetics with acute myocardial infarction
  122. Treatment with atorvastatin is associated with a better prognosis in chronic heart failure with systolic dysfunction: results from The Daunia Heart Failure Registry
  123. Bicuspid aortic valve and lusory artery: an unusual association
  124. Eisenmengerʼs syndrome in pregnancy
  125. Tako-Tsubo cardiomyopathy or allergic acute coronary syndrome: that is the question
  126. Recurrent Tako-Tsubo cardiomyopathy apparently induced by opposite triggers
  127. Ivabradine in pulmonary arterial hypertension: can we delay the need for parenteral prostanoid therapy?
  128. Statins in Heart Failure
  129. Gastrointestinal bleeding and coagulation disorders in a patient with left-ventricular assist device
  130. Ivabradine in systemic sclerosis related pulmonary arterial hypertension
  131. Cardiopulmonary exercise test predicts sustained ventricular arrhythmias in chronic heart failure
  132. Late onset of coronary vasospasm after administration of methyl-ergometrine for gynecologic bleeding
  133. Acute Phase Proteins In Acute Coronary Syndrome: An up-to-date
  134. Tako-Tsubo cardiomyopathy in a teen girl with pheochromocytoma
  135. “Ischemic” ST elevation in a woman with left ventricular hypertrophy
  136. Tako-Tsubo cardiomyopathy following an allergic asthma attack after cephalosporin administration
  137. Tissue Doppler Imaging in Coronary Artery Diseases and Heart Failure
  138. Tissue Doppler Time Intervals Predict the Occurrence of Rehospitalization in Chronic Heart Failure: Data from the Daunia Heart Failure Registry
  139. Transient apical ballooning accompanying respiratory infection
  140. Coronary atherosclerosis and a rare combination of congenital coronary anomalies in ST-elevation acute myocardial infarction
  141. Safe and well-tolerated treatment with ivabradine in systemic sclerosis affected by pulmonary hypertension
  142. Late calcification of the mitral–aortic junction causing transient complete atrio-ventricular block after mediastinal radiation of Hodgkin lymphoma: Multimodal visualization
  143. Pulmonary arterial hypertension: an update
  144. Left ventricular rupture in an anterior wall acute myocardial infarction with severe intra-ventricular gradient
  145. Clinical Application of Tissue Doppler Imaging in Coronary Artery Diseases and Heart Failure
  146. Early onset of coronary heart disease in a young woman with familial hypercholesterolemia: coronary findings and effect of short term treatment with high dose atorvastatin
  147. Aortic dissection after cocaine abuse
  148. In search of the best prognostic factor in patients with congestive heart failure
  149. Congenital coronary anomalies: a complementary role of multimodality imaging
  150. Unusual and voluminous pulmonary trunk aneurysm
  151. Les liaisons dangereuses: Tako-Tsubo syndrome after an adulterous intercourse in an elderly male
  152. Natriuretic peptides in heart failure: where we are, where we are going
  153. Pharmacological treatment of chronic systolic heart failure: are we scraping the bottom of the barrel?
  154. Combined exogenous and endogenous catecholamine release associated with Tako-Tsubo like syndrome in a patient with atrio-ventricular block undergoing pace-maker implantation
  155. Anti-hypertensive drugs and left ventricular hypertrophy: a clinical update
  156. Massive pulmonary embolism and atrial mass attached to permanent transvenous lead
  157. Trombo aórtico y embolia pulmonar aguda en individuo heterocigoto para la mutación C677-T del gen de la MTHFR
  158. Time intervals and myocardial performance index by tissue Doppler imaging
  159. Inflammatory Cytokines Imbalance in the Very Early Phase of Acute Coronary Syndrome: Correlations with Angiographic Findings and In-Hospital Events
  160. A Rare Cause of Acute Heart Failure: Malignant Schwannoma of the Pericardium
  161. Concomitant left anterior descending coronary artery and right coronary artery occlusion with typical anterior ST depression and inferior ST elevation
  162. Spontaneous resolution of a caseous calcification of the mitral annulus
  163. Troponin in Newborns and Pediatric Patients
  164. An unusual case of left anterior descending coronary artery occlusion—anterior ST depression and inferior ST elevation
  165. An Extramedullary Lesion in Multiple Myeloma: Voluminous Pericardial Mass
  166. Carbohydrate antigen-125: additional accuracy in identifying patients at risk of acute heart failure in acute coronary syndrome
  167. Alcohol abuse and heart failure
  168. Alternative presentation of Tako-Tsubo syndrome with spontaneous echo-contrast and “onion” shaped apical ballooning
  169. A “Bad” case of Tako–Tsubo syndrome
  170. Acute Phase Proteins In Atherosclerosis (Acute Coronary Syndrome)
  171. A voluminous and organized pericardial hematoma after open-heart surgery
  172. Massive pulmonary embolism immediately diagnosed by transthoracic echocardiography and treated with tenecteplase fibrinolysis
  173. A case of congenital cardiomyopathy with acute heart failure
  174. A Case of Pseudo-Hypertrophic Cardiomyopathy: A Congenital Heart Disease
  175. The Incidence and Clinical Course of Caseous Calcification of the Mitral Annulus: A Prospective Echocardiographic Study
  176. Real-time three-dimensional echocardiography: An update
  177. A rare mark of anomalies of cardiac venous drainage: unusual course of pacemaker lead
  178. Multidisciplinary approach in a case of successful surgical treatment of a voluminous intracardiac fungal mass in an infant: reply
  179. Acute phase proteins and systolic dysfunction in subjects with acute myocardial infarction
  180. Membranes of Left Atrial Appendage: Real Appearance or “Pitfall”
  181. Voluminous Mass Adherent to the Eustachian Valve
  182. Inflammatory Cytokine Imbalance after Coronary Angioplasty: Links with Coronary Atherosclerosis
  183. Real-time three-dimensional echocardiography: a pilot feasibility study in an Italian cardiologic center
  184. Acute phase proteins in patients with acute coronary syndrome: Correlations with diagnosis, clinical features, and angiographic findings
  185. A Coronary Artery Fistula With Aneurysm Draining Into the Coronary Sinus: Role of Transesophageal Echocardiography
  186. LIVE transthoracic three-dimensional visualization of a tumor mass in the inferior vena cava and heart
  187. Spontaneous coronary dissection complicating unstable coronary plaque in young women with acute coronary syndrome: Case reports
  188. Real-time three-dimensional transthoracic echocardiographic visualisation of accessory mitral valve tissue in a 22-year-old man with multiple sclerosis
  189. Voluminous mycetoma in a newborn with down syndrome: Role of echocardiography
  190. Early and late determinants of C-reactive protein release in patients with acute coronary syndrome
  191. C-reactive protein in patients with acute coronary syndrome: Correlation with diagnosis, myocardial damage, ejection fraction and angiographic findings
  192. Three-Dimensional Transthoracic Echocardiographic Visualization of a Voluminous Left Atrial Thrombus
  193. A rare complication after pacemaker implantation: unusually shaped lead coil